---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-046525"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T03:02:59.635840+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Novartis terminates collaboration with Pliant; discontinues NASH program PLN-1474

## Summary
- Novartis notified Pliant on Feb 17, 2023 of termination of Collaboration and License Agreement, effective April 18, 2023.
- Novartis is divesting clinical NASH assets and discontinuing development of PLN-1474 (integrin αvβ1 inhibitor for liver fibrosis).
- Pliant had received $50M upfront and $29M in contingent payments; up to $416M in future milestones and royalties now terminated.
- All rights and licenses, including PLN-1474 and validated research target compounds, revert to Pliant.
- Research term for up to three additional integrin targets concludes Q1 2023; one target validated with multiple development candidates.

## SEC filing metadata
- accession: 0001193125-23-046525
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312523046525/0001193125-23-046525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312523046525/d463670d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-046525
- JSON: https://secwatch.observer/filing/0001193125-23-046525.json
- Plain text: https://secwatch.observer/filing/0001193125-23-046525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.